MCID: CHL033
MIFTS: 24

Childhood Malignant Schwannoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Childhood Malignant Schwannoma

MalaCards integrated aliases for Childhood Malignant Schwannoma:

Name: Childhood Malignant Schwannoma 12 15
Childhood Neurofibrosarcoma 71
Pediatric Mpnst 12

Classifications:



External Ids:

Disease Ontology 12 DOID:7732
NCIt 49 C8094
UMLS 71 C0279987

Summaries for Childhood Malignant Schwannoma

MalaCards based summary : Childhood Malignant Schwannoma, also known as childhood neurofibrosarcoma, is related to osteofibrous dysplasia and cystadenocarcinoma. An important gene associated with Childhood Malignant Schwannoma is NF1 (Neurofibromin 1), and among its related pathways/superpathways are Interleukin-4 and 13 signaling and Glioblastoma Multiforme. The drugs Ifosfamide and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include bone.

Related Diseases for Childhood Malignant Schwannoma

Graphical network of the top 20 diseases related to Childhood Malignant Schwannoma:



Diseases related to Childhood Malignant Schwannoma

Symptoms & Phenotypes for Childhood Malignant Schwannoma

Drugs & Therapeutics for Childhood Malignant Schwannoma

Drugs for Childhood Malignant Schwannoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 40)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ifosfamide Approved Phase 3 3778-73-2 3690
2
Etoposide Approved Phase 3 33419-42-0 36462
3
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
4
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
5
Epirubicin Approved Phase 3 56420-45-2 41867
6
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
7
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
8
Histamine Approved, Investigational Phase 3 51-45-6 774
9
Cyproheptadine Approved Phase 3 129-03-3 2913
10 Alkylating Agents Phase 3
11 Antirheumatic Agents Phase 3
12
Isophosphamide mustard Phase 3 0
13 Anti-Bacterial Agents Phase 3
14 Antibiotics, Antitubercular Phase 3
15 Etoposide phosphate Phase 3
16 Immunologic Factors Phase 3
17 Immunosuppressive Agents Phase 3
18 Anti-Infective Agents Phase 3
19 Tubulin Modulators Phase 3
20 Antimitotic Agents Phase 3
21 Neurotransmitter Agents Phase 3
22 Histamine Antagonists Phase 3
23 Anti-Allergic Agents Phase 3
24
Histamine Phosphate Phase 3 51-74-1 65513
25 Histamine H1 Antagonists Phase 3
26 Dermatologic Agents Phase 3
27 Gastrointestinal Agents Phase 3
28
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
29
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
30
Lenograstim Approved, Investigational Phase 2 135968-09-1
31 Protein Kinase Inhibitors Phase 2
32 Imatinib Mesylate Phase 2 220127-57-1 123596
33
Liposomal doxorubicin Phase 2 31703
34
Celecoxib Approved, Investigational Phase 1 169590-42-5 2662
35 Cyclooxygenase 2 Inhibitors Phase 1
36 Analgesics Phase 1
37 Analgesics, Non-Narcotic Phase 1
38 Anti-Inflammatory Agents Phase 1
39 Cyclooxygenase Inhibitors Phase 1
40 Anti-Inflammatory Agents, Non-Steroidal Phase 1

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Localized Non-Rhabdomyosarcoma Soft Tissue Sarcomas Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 MMT 95 Study For Rhabdomyosarcoma and Other Malignant Soft Tissue Tumors of Childhood Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
3 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
4 Phase II Trial of Gleevec (Formerly Known as STI571) in Patients With Soft Tissue and Bone Sarcomas: A Multi-Disciplinary Trial of the North American Sarcoma Study Group of the Connective Tissue Oncology Society Completed NCT00031915 Phase 2 imatinib mesylate
5 Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
6 A Phase I Trial of Postoperative Radiation With Dose-Escalation of A Cox-2 Inhibitor, Celebrex™ (CELECOXIB) in Patients With Soft Tissue Sarcoma of the Extremity Completed NCT00450736 Phase 1 celecoxib
7 Clinical and Biological Predictors of Therapy-Related Leukemia Completed NCT00003793
8 Prevention of Mucositis in Children With AES-14 (IND#36978), a Glutamine Based Oral Care Regimen, for Patients Diagnosed With Solid Tumors: A Randomized Placebo-Controlled Clinical Study Withdrawn NCT00334984 glutamine

Search NIH Clinical Center for Childhood Malignant Schwannoma

Genetic Tests for Childhood Malignant Schwannoma

Anatomical Context for Childhood Malignant Schwannoma

MalaCards organs/tissues related to Childhood Malignant Schwannoma:

40
Bone

Publications for Childhood Malignant Schwannoma

Articles related to Childhood Malignant Schwannoma:

# Title Authors PMID Year
1
Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: A nationwide cohort study. 61
31889416 2020
2
Outcome and prognostic factors in pediatric malignant peripheral nerve sheath tumors: An analysis of the European Pediatric Soft Tissue Sarcoma Group (EpSSG) NRSTS-2005 prospective study. 61
31241238 2019
3
Immunohistochemical assessment of cyclin D1 and p53 is associated with survival in childhood malignant peripheral nerve sheath tumor. 61
30883338 2019
4
Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST). 61
24303016 2013

Variations for Childhood Malignant Schwannoma

Expression for Childhood Malignant Schwannoma

Search GEO for disease gene expression data for Childhood Malignant Schwannoma.

Pathways for Childhood Malignant Schwannoma

Pathways related to Childhood Malignant Schwannoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.49 CCND1 BIRC5
2 11.45 NF1 CCND1
3 11.27 KCNIP4 CCND1
4
Show member pathways
11.12 CCND1 BIRC5
5 11 NF1 CCND1
6 10.86 CCND1 BIRC5
7 10.55 SPP1 CCND1
8 10.19 CCND1 BIRC5

GO Terms for Childhood Malignant Schwannoma

Biological processes related to Childhood Malignant Schwannoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 osteoblast differentiation GO:0001649 9.26 SPP1 NF1
2 response to organic substance GO:0010033 9.16 SPP1 CCND1
3 liver development GO:0001889 8.96 NF1 CCND1
4 response to steroid hormone GO:0048545 8.62 SPP1 CCND1

Sources for Childhood Malignant Schwannoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....